Jonathan Ebinger

Jonathan Ebinger General Information

Description

Mr. Jonathan Ebinger serves as General Partner at BlueRun Ventures. Mr. Ebinger is an Angel Invetor. He is the Founder & serves as Managing General Partner at Transform Capital (San Francisco). He brings 20+ years of investing experience to the role from his time as a General Partner at BlueRun Ventures. He serves as a Board Member at Loyal & PayStand. Early in his career, he worked for MCI Communications, developing innovative services in the wake of the AT&T breakup, which catalyzed the next generation of innovation in voice and data communications. Starting his own internet business in the Web 1.0 world in 1996, he successfully exited Qwest Communications, where he ran consumer marketing until he signed on with BlueRun Ventures in 2000. Initially investing in mobile communications start-ups globally, his portfolio regularly took him to board meetings ranging from San Francisco to Reykjavik to Beijing to Bangalore. Over six funds and over $1.5B in funds raised, he developed an area of expertise in financial services and enterprise software, leading Series A investments in Coupa, FreedomPay, Kabbage, PayStand, and others. He served as a board member at Coupa. The relationships built with founders and co-investors at BlueRun laid the foundation for what became Transform Capital. He found that with an approach of a smaller follow-on investor, opportunities arise that would otherwise be closed to larger investors with board and ownership mandates. He has found that providing value well over the check size and directing half of the firm's GP profits to philanthropy is a formula for success. He received his B.S. in Finance from Virginia Tech and his MBA from The Darden School of Business at the University of Virginia. He lives in the heart of Silicon Valley in Woodside, California, with his wife and occasionally his two adult daughters, as school breaks permit. He serves as a Board Member at Blue Fever. He served as a Board Member at Petra Systems and Gennev.